Suven Life Sciences is currently trading at Rs. 183.90, up by 3.45 points or 1.91% from its previous closing of Rs. 180.45 on the BSE.
The scrip opened at Rs. 180.75 and has touched a high and low of Rs. 184.80 and Rs. 180.10 respectively. So far 31120 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 250.80 on 29-Jan-2018 and a 52 week low of Rs. 155.00 on 11-Aug-2017.
Last one week high and low of the scrip stood at Rs. 202.55 and Rs. 179.65 respectively. The current market cap of the company is Rs. 2325.45 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 7.35% and 32.65% respectively.
Suven Life Sciences has secured one product patent from New Zealand and one product patent from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2027 respectively.
The granted claims of the patents include the class of selective 5HT6 compounds and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia respectively.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
